ENTROPY NEURODYNAMICS: World- First Clinical Results in Treatment- Resistant Binge Eating Disorder Achieving Leadership in the Treatment of Neuropsychiatry Disorders Bioshares 2026 Investor Roadshow August 2026 This presentation has been authorised for release by the Board of Entropy...
BioShares 2026 Investor Presentation Deck
Filed with ASX ·
6ix hasn’t read this filing yet.
Entropy Neurodynamics Limited on 6ix
In the deck
Earlier from Entropy Neurodynamics
- 72 patient multi-indication trial approved to fast track TRP-8803 commercialisation
- 72-Patient Trial Fast-Tracks TRP-8803 Commercialisation
- Trading Halt
- South Africa Grants ENP Broad Fibromyalgia Patent to 2043
- 100% Clinical improvement, 50% Remission in BED study
Later from Entropy Neurodynamics
- Application for quotation of securities - ENP
- Cleansing Notice
- Change of Director's Interest Notice - HJ
- TRP 8803 manufacturing secured for Phase 2/3 advancement
- Entropy Advances TRP-8803 to US Phase 2 in Depression
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics